Marketed as Gardasil, the vaccine aims to halt the spread of the sexually-transmitted human papilloma virus (HPV), which causes cervical cancer. It also protects against two types of HPV that cause genital warts.
Professor Frazer, a Queensland- based scientist, first began work on the vaccine in the early 1990s. He has administered the first immunisation.
"It's a big day for me," Prof Frazer told news agency AAP.
Gardasil has been approved by Australia's Therapeutic Goods Administration (TGA) for use on boys aged nine to 15 and girls aged nine to 26, however the Australian manufacturer has applied to make the vaccine free only to females because trials on men are not complete.
In worldwide clinical trials involving more than 20,000 mostly sexually active women, Gardasil was 100 percent effective in preventing cervical cancers, and 99 percent effective in preventing two types of warts.
Gynaecological oncologist Gerry Wain applauded today's announcement, "Gardasil presents a paradigm shift in the management of women's health," said Dr Wain, scientific director of the NSW Cervical Screening Program.
“In Australia, there are 18,500 cases of low grade cervical abnormalities, 15,000 cases of high grade cervical abnormalities and 800 cases of cervical cancer detected annually " Dr Wain added.
The vaccine is given as a course of three injections in the upper arm or thigh over six months.